Testing whether opioids plus support change learning behavior
Treatments studied
Part of Mental health clinical trials.
This early study tests how opioid medicine, along with social support, affects how people learn or “unlearn” certain responses. If you’re healthy and meet safety requirements, it may help researchers understand how support could change the effects of pain-related medicines on behavior.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 35 years old
- Fluent in English enough to follow study instructions
- Do not have any past diagnosis of mental health conditions (like anxiety, depression, phobias, or other mental disorders)
- Do not be pregnant or planning pregnancy during the study
- Avoid being on regular prescription medicines for mental health or for liver problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a single treatment with ibogaine, a plant-based medicine, combined with a year of app and wearable support, helps people reduce or stop opioid use. It is for adults who have not had success with other treatments and are seeking a new option.
This study tests whether adding cannabidiol (CBD) to your usual methadone or buprenorphine treatment helps you recover from opioid use disorder. If you're already in stable treatment with those medications, the trial aims to see if CBD can improve your outcomes.
This trial tests whether a combination of buprenorphine (through your care plan) and a monthly extended-release naltrexone (XR-NTX) shot can help prevent opioid relapse. It may help people who are ready to move toward a naltrexone-based relapse-prevention treatment after detox.
This study tests whether the medication naltrexone can help reduce self-harm urges or actions in people who hurt themselves without intending suicide. It may offer a new option if current treatments haven't been enough.
This study tests whether a medication called naltrexone can help reduce the urge or behavior of self-injury (hurting yourself on purpose) in people who have not improved with standard treatment. It may offer a new option to manage these urges.
This Phase 1 study tests how adding psilocybin to a standard opioid treatment (buprenorphine-naloxone) affects recovery and symptoms in people with moderate-to-severe opioid use disorder. It may help researchers understand whether this combination is safe and beneficial alongside medication for opioid withdrawal and cravings.
Hear when a new Fear trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.